+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2016-06-14Number of Pages: 70

Viral Conjunctivitis Pipeline Drugs Market (Drug Type - FST-100 and APD-209) - Global Industry Analysis, Pipeline Review, Patent Analysis, and Forecast 2020 - 2023

Table of Content

1. Preface
    1.1. Report Description
    1.2. Research Methodology
    1.3. Assumptions 
    1.4. Market Segmentation

2. Executive Summary
    2.1. Viral Conjunctivitis Pipeline Drugs Market Share, by Geography, (Value %), 2023
    2.2. Viral Conjunctivitis Pipeline Drugs Market: Market Snapshot

3. Viral Conjunctivitis Pipeline Drugs Market – Industry Analysis
    3.1. Introduction
           3.1.1. Sign and Symptoms 
           3.1.2. Diagnosis 
           3.1.3. Management 
    3.2. Market Dynamics
           3.2.1. Market Drivers
                   3.2.1.1. Large Unmet Needs 
                   3.2.1.2. Strong Pipeline 
           3.2.2. Restraints
                   3.2.2.1. Low diagnosis rate
                   3.2.2.2. Self-Limiting Condition 
           3.2.3. Opportunity
                   3.2.3.1. Investment in Rigorous R&D Activities
                   3.2.3.2. Strengthen Commercialization Activities
    3.3. Epidemiology 
    3.4. Patent Analysis of Pipeline Drugs 

4.  Market Segmentation – By Pipeline Drug 
    4.1. Introduction
    4.2. Market Revenue of FST-100 (SHP-640), 2020–2023, (US$ Mn)
    4.3. Market Revenue of APD-209, 2021–2023, (US$ Mn)
    4.4. Early Stage Preclinical Trials (Tabular Form)

5. Market Segmentation – By Country 
    5.1. Introduction
    5.2. U.S. Viral Conjunctivitis Pipeline Drugs Market, 2020–2023, (US$ Mn) 
    5.3. U.K Viral Conjunctivitis Pipeline Drugs Market, 2021–2023, (US$ Mn) 
    5.4. Germany Viral Conjunctivitis Pipeline Drugs Market, 2021–2023, (US$ Mn) 
    5.5. Australia Viral Conjunctivitis Pipeline Drugs Market, 2022–2023, (US$ Mn) 
    5.6. Japan Viral Conjunctivitis Pipeline Drugs Market, 2022–2023, (US$ Mn) 
    5.7. Brazil Viral Conjunctivitis Pipeline Drugs Market, 2020–2023, (US$ Mn) 

6. Recommendations

7. Company Profiles
    7.1. Adenovir Pharma AB
    7.2. Allergan plc
    7.3. NanoViricides, Inc.
    7.4. Shire plc
    7.5. NovaBay Pharmaceuticals, Inc.
    7.6. Novartis AG
    7.7. Panoptes Pharma GES.M.B.H.
    7.8. NicOx S.A. 

List of Figures

FIG. 1 Viral Conjunctivitis Pipeline Drugs Market Share, by Geography, (Value %), 2023 (E)
FIG. 2 Industry Analysis: Viral Conjunctivitis Pipeline Drugs Market
FIG. 3 Viral Conjunctivitis: Signs and Symptoms
FIG. 4 Market Revenue of FST-100, (US$ Mn), 2020–2023
FIG. 5 Market Revenue of APD-209, (US$ Mn), 2021–2023
FIG. 6 U.S. Viral Conjunctivitis Pipeline Drugs Market Revenue, (US$ Mn), 2020–2023
FIG. 7 U.K. Market Revenue, (US$ Mn), 2021–2023
FIG. 8 Germany Market Revenue, (US$ Mn), 2021–2023
FIG. 9 Australia Market Revenue, (US$ Mn), 2022–2023
FIG. 10 Japan Market Revenue, (US$ Mn), 2022–2023
FIG. 11 Brazil Market Revenue, (US$ Mn), 2020–2023
FIG. 12 Allergan Financial Overview: (US$ Mn), 2012–2014
FIG. 13 NanoViricides, Inc., Financial Overview: (US$ Mn), 2013–2015
FIG. 14 Shire plc, Financial Overview: (US$ Mn), 2013–2015
FIG. 15 NovaBay Pharmaceuticals, Inc., Financial Overview: (US$ Mn), 2013–2015
FIG. 16 Novartis AG, Financial Overview: (US$ Mn), 2013–2015
FIG. 17 NicOx S.A., Financial Overview: (US$ Mn), 2013–2015 

List of Tables

TABLE 1 Viral Conjunctivitis Pipeline Drugs Market: Market Snapshot
TABLE 2 Viral Conjunctivitis: Management 
TABLE 3 Epidemiology
TABLE 4 Patent Analysis of Pipeline Drugs
TABLE 5 Viral Conjunctivitis Pipeline Drugs Market Revenue, by Pipeline Drug, (US$ Mn), Expected Launch–2023
TABLE 6 Early Stage Preclinical Trials
TABLE 7 Viral Conjunctivitis Pipeline Drugs Market Revenue, by Country, (US$ Mn), 2020–2023


 
 
Back To Top